Results 251 to 260 of about 150,085 (313)

High-intensity hydrophilic versus lipophilic statins in patients with primary biliary cholangitis: a multi-institutional analysis. [PDF]

BMC Gastroenterol
Kawas H, Alabbas M, Abu-Hammour MN, Eren B, Hazem W, Sims OT, Chiang DJ.   +6 more
europepmc   +1 more source

Proteomic Profiling Captures Residual Cardiovascular Risk Beyond the PREVENT Model in Individuals With Cardiovascular–Kidney–Metabolic Syndrome Stages 2–3

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Cardiovascular–kidney–metabolic (CKM) syndrome reflects complex pathobiological interactions among metabolic disorders, kidney injury, and cardiovascular disease (CVD). Stages 2 and 3 represent critical phases of disease progression characterised by high pathological heterogeneity.
Xuefei Han, Jiacheng Ding, Jingqian Li, Yiyin Gao, Yunqian Li   +4 more
wiley   +1 more source

Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin-1-Mediated PI3K/AKT Signaling Pathway in Cisplatin-Resistant Cervical Cancer Cells. [PDF]

FASEB J
Zhou Y, Liu H, Pan S, Ruan L, Ruan J, Chen J, Ji H, Zhu X.   +7 more
europepmc   +1 more source

Clinical efficacy of combining fenofibrate with statins in patients with diabetes and hyperlipidemia: a meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Huang J, Meng K, Qiu H.
europepmc   +1 more source

Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Urogenital adverse events are common with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (
Christine Ljungberg, Kasper Bonnesen, Morten Schmidt, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Mette Nørgaard, Reimar Wernich Thomsen   +7 more
wiley   +1 more source

Editorial: New drugs in lipid lowering therapy. [PDF]

Front Cardiovasc Med
Bytyçi I, Banach M, Pećin I.
europepmc   +1 more source

Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Jihad Abu Zayed, Nada A. Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh   +4 more
wiley   +1 more source

Greater Glycaemic Responses to Bodyweight Change in South Asians Than White Europeans at High Risk of Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Bodyweight change is an important determinant of cardiometabolic health, but its metabolic impact may differ by ethnicity. This study investigated whether ethnicity (White European, South Asian) modifies the association between change in bodyweight and changes in HbA1c and oral glucose tolerance test (OGTT)–derived measures. Materials and
Franciskos Arsenyadis, Joseph Henson, Pratik Choudhary, Melanie J. Davies, Kamlesh Khunti, Tom Yates   +5 more
wiley   +1 more source

The therapeutic potential of atorvastatin in treatment of <i>G. lamblia</i> infected mice; <i>in silico</i>, parasitological, and histopathological study. [PDF]

Front Vet Sci
Mohamed K, Khodary M, Hamed D, Alhazmi A, Gattan HS, Alruhaili MH, Fadel EF, Elshabrawy HA, El-Kady AM.   +8 more
europepmc   +1 more source